Eli Lilly's biggest obesity catalyst of the year drops in the next eight weeks. On the April 30 Q1 earnings call, Lilly executives confirmed that top-line TRIUMPH-1 results are expected later this quarter — the 80-week pivotal trial that will anchor retatrutide's New Drug Application.
This is the readout that decides whether retatrutide leapfrogs tirzepatide as the new ceiling for obesity pharmacotherapy or stalls under the weight of glucagon-receptor side effects. Here is what to expect, why TRIUMPH-1 matters more than the other TRIUMPH trials already reported, and what it means for anyone tracking the research-peptide market today.
What TRIUMPH-1 Is Actually Measuring
TRIUMPH-1 is the obesity registration trial in Lilly's eight-trial TRIUMPH Phase 3 program. The setup, per Lilly's investor disclosures and ClinicalTrials.gov:
- Duration: 80 weeks of treatment (the longest of any TRIUMPH trial)
- Population: Adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related comorbidity, without type 2 diabetes
- Doses: 4 mg, 8 mg, and 12 mg retatrutide vs matched placebo, all once-weekly subcutaneous
- Primary endpoints: Mean percent change in body weight; proportion achieving ≥5% weight loss
- Key secondaries: ≥10%, ≥15%, ≥20%, ≥25% weight-loss thresholds; cardiometabolic markers; patient-reported outcomes
The trial enrolls a general obesity population without diabetes, which is the direct analogue of the trials that defined the current obesity-drug ceiling: SURMOUNT-1 for tirzepatide (-22.5%, 72 weeks) and STEP-1 for semaglutide (-15%, 68 weeks). That structural similarity is the entire point. Lilly designed TRIUMPH-1 to produce a number that can be placed directly next to those benchmarks on a regulatory label.
Why It Matters More Than TRIUMPH-4 or TRANSCEND-T2D-1
Retatrutide already has two positive Phase 3 readouts in the bag:
| Trial | Population | Duration | Headline | Reported |
|---|---|---|---|---|
| TRIUMPH-4 | Obesity + knee osteoarthritis | 68 wk | -28.7% at 12 mg | Dec 2025 |
| TRANSCEND-T2D-1 | Type 2 diabetes | 40 wk | -1.7 to -2.0% A1C, -16.8% weight at 12 mg | Mar 2026 |
| TRIUMPH-1 | General obesity | 80 wk | TBD | Q2 2026 |
TRIUMPH-4 was a remarkable readout, but the population was narrow — adults with obesity and knee osteoarthritis. The 28.7% number is impressive, but regulators and payers will want to see what retatrutide does in the broader, non-arthritic, non-diabetic obesity population. That is what TRIUMPH-1 is for.
TRANSCEND-T2D-1 settled the diabetes question. TRIUMPH-1 settles the obesity question — and obesity is the larger commercial market by an order of magnitude.
A second reason TRIUMPH-1 matters more: the 80-week duration. Most prior obesity trials run 68–72 weeks. The extra eight to twelve weeks let Lilly demonstrate two things FDA cares about: (1) whether weight loss continues to deepen past the typical plateau point, and (2) whether tolerability holds up over a longer treatment horizon. Both are pressure points on the glucagon mechanism that retatrutide adds beyond tirzepatide's GIP/GLP-1 dual.
What Number Should You Expect?
The Phase 2 retatrutide trial in obesity (Jastreboff et al., NEJM 2023) hit 24.2% at 48 weeks. TRIUMPH-4 hit 28.7% at 68 weeks in obesity + knee OA. With TRIUMPH-1 running another 12 weeks longer (80 vs 68) in a healthier general-obesity population, the directional expectation is clear: the headline number should be higher than 28.7%.
Sell-side analyst consensus has clustered around 28% to 32% mean weight loss at the 12 mg dose. The bull case is 32%+, which would be the highest weight-loss number ever reported in a Phase 3 obesity trial and would put retatrutide solidly past every approved competitor and every late-stage rival (CagriSema 22.7%, survodutide 16.6%, eloralintide 20% in Phase 2).
The bear case is anything below 25%. That would suggest the glucagon-receptor mechanism doesn't add as much in healthier populations as it did in TRIUMPH-4, and would shrink retatrutide's differentiation versus tirzepatide.
What is virtually certain to show up in the readout regardless: dysesthesia. TRIUMPH-4 reported abnormal touch sensation in 8.8% of the 9 mg arm and 20.9% of the 12 mg arm versus 0.7% on placebo — a signal that wasn't present in Phase 2 and that appears tied to glucagon-receptor activation. We covered this in detail in the retatrutide dysesthesia side-effect breakdown. TRIUMPH-1's longer follow-up will tell us whether the tingling resolves on treatment or persists, which materially affects the eventual label.
What This Means for the Retatrutide NDA Timeline
Lilly confirmed on the Q1 call that TRIUMPH-1 anchors the obesity NDA filing planned for Q4 2026. That puts the regulatory clock at:
- Q2 2026: TRIUMPH-1 top-line readout
- Q3 2026: Detailed presentation at scientific meetings (likely EASD September; possible ADA session expansion)
- Q4 2026: NDA submission to FDA
- 2027: Standard FDA review (6–10 months)
If Lilly uses the Commissioner's National Priority Voucher — the same accelerated pathway that compressed orforglipron's review to 50 days — retatrutide approval could land as early as Q1 2027. Lilly hasn't confirmed it will use the voucher for retatrutide, but it has openly said the program is part of its strategic toolkit. Orforglipron set the precedent.
For comparison, tirzepatide's obesity indication took roughly nine months from filing. CagriSema is currently sitting at the FDA with a decision expected late 2026. Retatrutide approved in 2027 would arrive into a market where CagriSema and oral semaglutide are already on shelves — but with the highest weight-loss number of the bunch.
